Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Anil Bhaskar
Unified Customer Experience

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Mike Viscel
Increasing Engagement

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Frank X. Powers
Healthcare Challenger Brands

David Linetsky
Patient Activation

Frank Burrell
Scientific Storytelling

Laura Blair
Medication Adherence

Thomas Shea
Programmatic Marketing

Stacey Gandler
Brand Nourishment